Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Waleska S. Pérez, Saurabh Dahiya, Frederick Lundry Locke, Hil Hsu et al.
Journal
Journal of Clinical Oncology
Topics
CAR-T cell therapy research
article
Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Waleska S. Pérez, Saurabh Dahiya, Frederick Lundry Locke, Hil Hsu, Caron Alyce Jacobson, Dafna Bonneh‐Barkay, Michael Hemmer, Jennifer Holter‐Chakrabarty, John H. Baird, Michael Tees, Brian McClune, E Pizzi, Fateeha Furqan, Jenny Kim, Jiali Yan, Marcelo C. Pasquini, Yi Lin, Zhongyu Feng
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(16_suppl)
Institutions
City Of Hope National Medical Center (US), The University of Texas MD Anderson Cancer Center (US), Medical College of Wisconsin (US), University of Utah (US), Huntsman Cancer Institute (US), Moffitt Cancer Center (US), Sarah Cannon (US), Dana-Farber Cancer Institute (US), Mayo Clinic in Arizona (US), Colorado Blood Cancer Institute (US), University of Oklahoma Health Sciences Center (US), Stanford University (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). — Waleska S. Pérez, Saurabh Dahiya, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS